Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyroxamine SCHEMBL636692 | 0.91 | DRD3 (0.56) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| SCHEMBL2056216 | 0.85 | DRD3 (0.71) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL1151732 | 0.83 | MEN1 (0.60) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Diphenylpyraline SCHEMBL119077 | 0.82 | DRD3 (1.00) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL1151739 | 0.82 | MEN1 (0.58) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL1151799 | 0.82 | MEN1 (0.58) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| SCHEMBL1151611 | 0.81 | DRD3 (0.56) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Diphenylpyraline SCHEMBL212198 | 0.81 | MAPK1 (1.00) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL1152504 | 0.80 | MEN1 (0.56) | DRD3CYP2D6SLC6A3CHRM2HTR1A | |
| Diphenylpyraline SCHEMBL4543024 | 0.79 | DRD3 (0.93) | DRD3CYP2D6SLC6A3CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415693-A | Generation of human pluripotent stem cell-derived functional β cells showing glucose-dependent mitochondrial respiration and biphasic insulin secretion response | 詹森生物科技公司 | 2019-03-01 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20250213629-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | SIOLTA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240173368-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | SIOLTA THERAPEUTICS INC (US) | 2024-05-30 | — | — | US | disclosed |
| US-11806373-B2 | Therapeutic pharmaceutical compositions | SIOLTA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220362313-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | SIOLTA THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| CN-115135628-A | Compounds for fast and efficient click release | 泰克沃尔科斯制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-4041264-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | Siolta Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | DRD3 4723/4885CYP2D6 4855/4885SLC6A3 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.